Science 37 Holdings, Inc. (Nasdaq: SNCE), the clinical research
industry-leading Metasite™ is proud to announce its nomination for
the prestigious 2023 Prix Galien USA Awards in the category of
"Best Digital Health Solution.” The Prix Galien Awards, organized
by The Galien Foundation, recognize and celebrate groundbreaking
innovations in the life sciences industry that significantly
advance human health and well-being.
"We are honored to see Science 37 recognized as a nominee for
the Prix Galien USA Awards," said David Coman, CEO of Science 37.
"This nomination is a testament to our team's dedication to
accelerating clinical research by enabling universal trial access
for patients through our Metasite. We are proud to be part of an
exceptional group of innovators striving to make a positive impact
on patients' lives."
Science 37 has redefined the clinical trial landscape, as a
virtual site that transforms research by enabling patients to
participate in trials from the comfort of their homes. With
investigator oversight, the Metasite removes boundaries and
enhances experience with flexible telemedicine visits, remote data
capture, and convenient scheduling times. Powered by a proprietary
platform that enables eConsent, ePRO, telemedicine, scheduling, and
wearable/ device integration, the Metasite drives unified study
orchestration, greater compliance, and high-quality data—reaching
patients, wherever they are.
The 2023 Prix Galien USA Forum, taking place on October 26,
2023, at the Alexandria Center for Life Science in New York City,
will feature the nominees for "Best Digital Health Solution" among
others, and later that evening, during the Prix Galien USA Awards
Ceremony at the American Museum of Natural History in New York
City, the winners in all categories will be unveiled and
honored.
“We extend our congratulations to Science 37 for their
remarkable contributions to clinical research," said Galien
Foundation Chair, Bruno Cohen. "The Awards represent endless
determination in the pursuit of life-changing innovation, and we
are excited to announce the 2023 nominations.”
About Science 37Science 37 Holdings, Inc.’s
(Nasdaq: SNCE) mission is to accelerate clinical research by
enabling universal trial access for patients. Through our Metasite™
we reach an expanded population beyond the traditional site,
delivering on our goal of clinical research that works for
everyone—with greater patient diversity. Patients gain the
flexibility to participate from the comfort of their own homes, at
their local community provider, or at a traditional site when
needed. Our Metasite is powered by a proprietary technology
platform with in-house medical and operational experts that drive
uniform study orchestration, enabling greater compliance and
high-quality data. To learn more, visit www.science37.com, or email
science37@science37.com.About the Galien
Foundation The Galien Foundation fosters, recognizes, and
rewards excellence in scientific innovation to improve the state of
human health. Our vision is to be the catalyst for the development
of the next generation of innovative treatments and technologies
that will impact the state of medical practice and save lives.
The Foundation oversees and directs activities in the US for the
Prix Galien, an international awards program dedicated to progress
through innovative medicines development, with chapters in 14
countries and Africa. The Prix Galien was created in 1970 by Roland
Mehl in honor of Galien, the father of medical science and modern
pharmacology. Worldwide, the Prix Galien is regarded as the
equivalent of the Nobel Prize in biopharmaceutical research.
Cautionary Note Regarding Forward-Looking
Statements
This press release contains certain forward-looking statements
within the meaning of the federal securities laws, including
statements regarding the products offered by Science 37 and the
markets in which it operates, and Science 37’s anticipated growth
and profitability. These forward-looking statements generally are
identified by the words “believe,” “can,” “could”, “seek”,
“project,” “expect,” “anticipate,” “estimate,” “intend,”
“strategy,” “future,” “opportunity,” “plan,” “may,” “might”,
“should,” “will,” “would,” “will be,” “will continue,” “will likely
result” and similar expressions. Forward-looking statements are
predictions, projections and other statements about future events
that are based on current expectations and assumptions and, as a
result, are subject to risks and uncertainties. Many factors could
cause actual future events to differ materially from the
forward-looking statements in this press release, including but not
limited to: (i) the ability to maintain the listing of Science 37’s
securities on The Nasdaq Stock Market LLC, (ii) volatility in the
price of Science 37’s securities due to a variety of factors,
including changes in the competitive and highly regulated
industries in which Science 37 operates, variations in performance
across competitors, changes in laws and regulations affecting
Science 37’s business, changes in its capital structure, and
general economic and financial market conditions, including
fluctuations in currency exchange rates, economic instability, and
inflationary conditions (iii) the ability to implement business
plans, forecasts, and other expectations, and to identify and
realize additional opportunities, (iv) the risk that Science 37 may
never achieve or sustain profitability, (v) the risk that Science
37 will need to raise additional capital to execute its business
plan, which may not be available on acceptable terms or at all,
(vi) failure to realize anticipated cost savings, and (vii) risks
related to general economic and financial market conditions. The
foregoing list of factors is not exhaustive. You should carefully
consider the foregoing factors and the other risks and
uncertainties described in the “Risk Factors” section of Science
37’s Annual Report on Form 10-K for the fiscal year ended December
31, 2022 filed with the U.S. Securities and Exchange Commission
(the “SEC”) on March 6, 2023 and in the other documents filed by
Science 37 from time to time with the SEC. These filings identify
and address other important risks and uncertainties that could
cause actual events and results to differ materially from those
contained in the forward-looking statements. Forward-looking
statements speak only as of the date they are made. Readers are
cautioned not to put undue reliance on forward-looking statements,
and Science 37 assumes no obligation and does not intend to update
or revise these forward-looking statements, whether as a result of
new information, future events, or otherwise, except as required by
law. Science 37 does not give any assurance that Science 37 will
achieve its expectations.
MEDIA INQUIRIES:Grazia MohrenScience
37PR@science37.com
INVESTOR RELATIONS:Steve HalperLifeSci
AdvisorsInvestors@science37.com
Science 37 (NASDAQ:SNCE)
Historical Stock Chart
From Apr 2024 to May 2024
Science 37 (NASDAQ:SNCE)
Historical Stock Chart
From May 2023 to May 2024